

# Corrigendum

*Ther Adv Med Oncol*

2017, Vol. 9(11) 725

DOI: 10.1177/  
1758834017743368


© The Author(s), 2017.  
Reprints and permissions:  
[http://www.sagepub.co.uk/  
journalsPermissions.nav](http://www.sagepub.co.uk/journalsPermissions.nav)

Boér K. Fulvestrant in advanced breast cancer: evidence to date and place in therapy. *Therapeutic Advances in Medical Oncology* 2017; 9: 465-479. DOI: 10.1177/1758834017711097

This article, published in the July Issue of *Therapeutic Advances in Medical Oncology*, has the following corrections:

1. Table 1 (page 469):
  - a. Regarding the CONFIRM trial, the ‘Primary endpoint’ was incorrectly listed as ‘TTP’ (time to progression), and should have been listed as ‘PFS’ (progression-free survival).
  - b. Regarding the Paloma-3 trial, the data in the ‘CBR or ORR (%)’ column were incorrectly listed as ‘24.6 versus 10.9 (CBR)  $p = 0.0012$ ’, and should have been listed as ‘34.0 versus 19.0 (CBR),  $p < 0.001$ ’.
  - c. Regarding the PrECOG 0102 trial, the number of participants (‘n’) was incorrectly listed as ‘131’, and should have been listed as ‘130’.
2. On page 473 (left-hand column, first paragraph), the percentages listed for the most common grade 3 or 4 adverse events were taken from Cristofanilli *et al.* (reference 35 in the article reference list). This was not clear in the article.
3. On page 473 (left-hand column, third paragraph), the number of participants in the PrECOG 0102 trial was incorrectly listed as ‘131’, and should have been listed as ‘130’.
4. On page 473 (right-hand column, first paragraph), the following text was incorrect: “The combination was associated with greater toxicity; the most frequent grade 3 adverse events were stomatitis (9%), pneumonitis (6%), fatigue (5%), and hyperglycaemia (6%).” This text should instead have read “Grade 3/4 AEs were more common in the everolimus arm, including hyperglycemia (16%/0% vs 0%), stomatitis (11%/0% vs 0%), hypertriglyceridemia (9%/2% vs 0%), lymphopenia (9%/0% vs 0%), and pneumonitis (6%/2% vs 0%).”
5. On page 474 (right-hand column, first paragraph), the p-value for PFS for the HER2+ve subgroup was incorrectly listed as ‘ $p = 5.53$ ’ and should have been listed as ‘ $p = 0.53$ ’.

Visit SAGE journals online  
[journals.sagepub.com/  
home/tam](http://journals.sagepub.com/home/tam)

 SAGE journals

The author and the editors would like to apologise for these errors.

